DS 3201

Drug Profile

DS 3201

Alternative Names: DS-3201; DS-3201b

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator Daiichi Sankyo Inc
  • Class Antineoplastics
  • Mechanism of Action EZH2 enzyme inhibitors; Histone-lysine N-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Mar 2016 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in Japan (unspecified route) (NCT02732275)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top